research use only
Cat.No.S1120
| Related Targets | PI3K Akt GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK |
|---|---|
| Other mTOR Inhibitors | Torin 1 Torin 2 AZD8055 Ridaforolimus (Deforolimus, MK-8669) Sapanisertib (MLN0128, INK-128) Torkinib (PP242) MHY1485 Vistusertib (AZD2014) KU-0063794 OSI-027 |
|
In vitro |
DMSO
: 100 mg/mL
(104.36 mM)
Ethanol : 100 mg/mL Water : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about RAD001 (Everolimus) solubility in DMSO or water
Read more about RAD001 (Everolimus) working concentrations for cell culture treatment
| Information | RAD001 (Everolimus) is a potent mTOR inhibitor. It affects PI3K/AKT/mTOR signaling by blocking mTOR, inhibiting tumor growth. |
|---|---|
|
Read more about RAD001 (Everolimus) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
| Molecular Weight | 958.22 | Formula | C53H83NO14 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 159351-69-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | RAD001,SDZ-RAD | Smiles | CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC | ||
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
For the in vivo work, I know it needs to be dissolved in 30% propylene glycol (dilution in water) and 5% Tween 80. Would the final solution be a clear liquid or a turbid suspension?
Answer:
Our S1120 in 30% Propylene glycol+5% Tween 80+ddH2O at 5mg/ml is a clear solution. And for oral gavage, there is another common vehicle, 1% CMC Na. It can be dissolved in it at 30mg/ml as a suspension.